Skip to main content

Drug Interactions between concizumab and emicizumab

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

emicizumab concizumab

Applies to: emicizumab and concizumab

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Concomitant or consecutive use of concizumab and emicizumab may have additive effects on thrombin generation and increase the risk of thrombosis. In clinical studies, hemophilia A patients with FVIII inhibitors were required to discontinue emicizumab for at least 180 days before receiving concizumab. Clinical data about this interaction are lacking.

MANAGEMENT: When changing from another anti-tissue factor pathway inhibitor product to concizumab, the previous product's half-life should be taken into consideration. Due to the long half-life of emicizumab, some authorities recommend that it be ceased for at least 180 days prior to starting treatment with concizumab in Hemophilia A patients with FVIII inhibitors. Close monitoring for thromboembolic events is recommended in patients with known risk factors for thromboembolism (e.g., prior thrombosis, hyperlipidemia, hypertension, smoking). Patients should be advised to seek immediate medical attention if they develop symptoms of thromboembolism, such as shortness of breath, chest pain, hemoptysis, or arm or leg swelling or pain.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.